Company news
Ltr Pharma Limited (ASX:LTP) news
Ltr Pharma Limited news releases on 6ix. Latest, Oct 5, 2026: First ROXUS Prescriptions Fulfilled in the United States
Press releases & updates
First ROXUS Prescriptions Fulfilled in the United States
October 5, 2026
SPONTAN Phase II Final Results
September 30, 2026
FY26 Results Announcement
August 27, 2026
SPONTAN Real-World Study Reports 93% Response
August 10, 2026
LTR Executes U.S. Commercial Agreement with Strive
July 19, 2026
LTR Executes Definitive U.S. Commercial Agreement with Shed
July 16, 2026
Response to ASX Aware Letter
June 15, 2026
LTR Secures Exclusive U.S. Pharmacy Partner for ROXUS
June 10, 2026
LTR Secures First U.S. Commercial Agreement for ROXUS
June 8, 2026
SPONTAN® Phase II interim data demonstrates rapid onset and pharmacokinetic profile addressing FDA Pre-IND requirements across adult and ≥65 populations
May 4, 2026
SPONTAN Phase II data show rapid onset, support FDA pathway
April 30, 2026
SPONTAN Phase II Clinical Study Completes Recruitment
March 4, 2026
Appendix 4D and Half Yearly Report
February 25, 2026
SPONTAN Shows Positive Outcomes in Younger Men with ED
February 1, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 27, 2026
First Patients Dosed in SPONTAN Phase II Clinical Study
January 21, 2026
TGA Provides Regulatory Clearance for SPONTAN Phase II
December 9, 2025
Ethics Approval Received for SPONTAN Phase II Clinical Study
December 2, 2025
LTR increases LevOmega stake to 43% with $1m investment
October 5, 2025
LTR Pharma secures 33% ownership in LevOmega Pty Ltd
September 21, 2025
FY25 Results Announcement
August 28, 2025
Appendix 4E and Annual Report to Shareholders
August 28, 2025
SPONTAN Case Series - Strong Post-Prostatectomy Results
August 24, 2025
18-Month Shelf Life Strengthens SPONTAN Commercialisation
August 21, 2025
SPONTAN 5x Faster Onset Validated in EU Journal
August 19, 2025
LTP Completes Extractables Study Milestone for SPONTAN
June 29, 2025
Urological Expert Appointed to LTR Scientific Advisory Board
May 20, 2025
SPONTAN Expands Patient Access via National Pharmacy Network
May 19, 2025
LTR Signs Collaborative Agreement to Develop OMD Nasal Spray
May 7, 2025
Investor Presentation
March 26, 2025
Commercial Update and Regulatory Progress
March 25, 2025
LTR Pharma to Showcase SPONTAN Data at Urology Conference
February 27, 2025
LTR Signs Symbion National Pharmacy Distribution Agreement
January 21, 2025
Response to ASX Query Letters
December 30, 2024
Agreement with Men's Health Pharmacy for SPONTAN access
December 18, 2024
Early Launch of Online Mens Health Platform
December 11, 2024
LTR Pharma Announces Successful A$25 million Placement
December 9, 2024
Trading Halt
December 5, 2024
JV with Leading Men's Health Group for Online Platform
November 11, 2024
SPONTAN Final Study Results
October 13, 2024
FY24 Results Announcement
August 29, 2024
Appendix 4E and Annual Financial Report
August 29, 2024
SPONTAN Prescribed to First Patient by Authorised Prescriber
August 15, 2024
LTP Secures Global CoDevelopment Agreement with Aptar Pharma
August 12, 2024
Mens Health Expert Prescribes SPONTAN
August 7, 2024
SPONTAN prescribed to First Patient Under TGA
August 4, 2024
LTR Pharma completes A$10.5 million placement
July 23, 2024
SPONTAN achieves positive clinical study results
June 7, 2024
Reinstatement to quotation
June 7, 2024
Suspension from Quotation
June 6, 2024